

# **Osteoporosis and bone metabolism**




RSU prof. Aivars Lejnieks, Riga Eastern Clinical University Hospital ESIM Riga 26.01.2015





# Form and function of skeleton


### Skeleton: cortical and trabecular bone

- Skeleton is a dynamic organ. It consists of more than 200 bones with mechanical, protective and metabolic function
- □ There is:
  - Cortical bone outer layer of the bone (approx. 80% of the total mass of skeleton, regeneration rate 2-3% per year, attachment point for tendon and muscle, protects organs, solid, hard)
  - Trabecular bone connects with cortical bone from within (approx. 20% of the total mass of skeleton, solid, elastic, mineral storage, regenerates faster)










Demster DW. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 6th ed. 2006 7-11.


## **Bone anatomy:**





© American Society for Bone and Mineral Research Contributed by David W. Dempster, PhD

# **Bone function:**


- Skeleton formation, maintenance and resorption (bone micro- and macroarchitectonics).
- Supplies body and skeleton with Ca (bone contains 1-2 kg Ca compared to 1-2 g of extracellular Ca) and P.
- ~50% total Ca is protein-bound (mostly albumin and globulin). Ionized Ca ~1.2 mmol/L, its concentration is tightly regulated by hormones.








# Periosteum, cortical and trabecular bone




From the *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th Edition.* www.asbmrprimer.org Williams Textbook of Endocrinology 12th ed., 2011

# **Calcium absorption rate in different age**




NHANES-II median values. Heaney et al.; O'Brien et al. Heaney et al. .


# Calcium metabolism – homeostasis, Ca and P distribution and function




Williams texbook of endocrinology 12th ed. By J.D.Wilson et al,2011



### Differences in absorption rate of various Ca salts and ionized Ca and PTH



P. Heaney, 2000



AP

♠

Ν

个

N or 🛧

Ν

PTH

1

Ν

1


J

J



# **Bone biology**


http://adsoftheworld.com/media/print/sammy400\_osteoarthritis\_treatment\_bin\_laden\_vs\_bush



# My understanding of osteoporosis in 1997


Manu sapratnes ideju interpretāciju ar manas 11 gadīgās meitas Aijas rokām

# Bone cells and relation to hematopoietic system (stem cell)




- Osteoblasts (derivatives of mesenchymal stem cells) contain: osteoblasts, osteocytes and bone lining cells.
   Osteoblasts synthesize organic matrices and create new bone tissue
- Osteoclasts (hematopoietic system precursors) resorb bone tissue releasing enzymes of hydrolase.

### Bone remodelation process (approx. 200 days)




Baron R. Primer on the Metabolic Bone Diseases and Diorders of Mineral Metabolism. 5th ed. 2003:1-8. Bringhurst FR, et al. Harrison's Principles of Internal Medicine 16th ed. 2005: 2238-2249. Lindsay R, at al. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. 2nd ed. 1999:305-314


### **Concept of RANK/RANK ligands and OPG**



## **Osteoprotegerin (OPG) blocks RANK ligand**




#### Multiple factors contribute to RANK ligand excretion from osteoblast



© 2007 Amgen. All rights reserved.


Provided as an educational resource. Do not copy or distribute.

### Bone health depends on relationship of RANK ligand and OPG



Hofbauer LC *et al.* JAMA 2004; 292: 490–495; 2 Lacey DL *et al.* Cell 1998; 93: 165–176; Boyle WJ *et al.* Nature 2003; 423: 337–342


# RANK ligand is significant to development of osteoporosis and other conditions related to bone loss or destruction




Bone destruction caused by cancer




Hofbauer LC, Schoppet M. *JAMA*. 2004;292:490-495. Eghbali-Fatourechi G, et al. *J Clin Invest*. 2003;111:1221-1230. Hofbauer LC, et al. *Endocrinology*. 1999;140:4382-4389. Theriault RL. *Oncology*. 2004;18(Suppl 3):11-15.






Bone erosion due to RA




Gravallese EM, et al. *Arthritis Rheum*. 2000;43:250-258. Roodman GD. *N Engl J Med*. 2004;350:1655-1664. Kong Y-Y, et al. *Nature*. 1999;402:304-309 Kitazawa S, et al. *J Pathol*. 2002;198:228-236.




# **Definition and diagnosis of osteoporosis**

http://www.standtallwalktall.com/osteoporosis.html

#### It is ABC to remember!



### **BMD and porosity changes during aging**



16.95

10 - 19

20 - 29

30 - 39

40 - 49

50-59

60-69


70-79

80-99

13.01

Bousson V, Bergot V, Bergot C et al. Radiology 2000;217:179-187

# Osteoporosis is a systemic skeletal disease with increased fracture risk in whole skeleton



Boyle WJ, et al. Nature 2003;423:337-342

http://www.true-beauty-tips.com/osteoporosis-alternatives.html

# **Bone risk factors**

#### □ **RF**:

- Age
- Low BMD
- Previous fractures
- Low BMI
- **Fractures in family history**
- Smoking
- Alcohol abuse
- Rheumatoid arthritis
- Glucocorticoid treatment




# Medical conditions and drugs which increase fracture risk

#### Endocrine

- Hyperthyroidism, hyperparathyroidism, Cushing syndrome, diabetes mellitus, hyperprolactinemia, hypercalciuria
- Renal:
  - CKD, ESRD, renal osteodystrophy
- Rheumatologic/connective tissue diseases
  - Ankylosing spondylitis, RA, Ehlers Danlos, Marfan syndrome
- GIT/liver:
  - Gastrectomy, celiac disease, calcium malabsorption, cirrhosis
- Infiltrative:
  - Multiple myeloma, leucemia, mastocytosis
- **Nutritional/metabolic:** 
  - Eating disorders, vit.B<sub>12</sub> deficiency, vit.D deficiency, increased homocysteine level


- □ GC
- Long acting progestins
- Aromatase inhibitors
- GT-RH agonists
- Anticonvulsants
- Cytotoxic therapy
- Long acting heparine
- Lithium
- Protone pump inhibitors

Hodgson SF et al. Endocr Pract 2003;9:544-564 NOF The State of Osteoporos and Low Bone Mass in the US Washington DC NOF, 2005 Yang Y, Lewis D, Epstein S, Dawid C JAMA 2006;296:2947-2953



# **Diagnostics of osteoporosis**

### How to detect bone strength?




## **Diagnostics of osteoporosis**



- DXA Dual Energy X-ray Absorbtiometry
- Used for OP diagnostics
- Measures BMD mostly in LL vertebrae and hip
- Compares pacient's BMD *T-score* with healthy young person's BMD (population reference)

NOF Clincal Guide to Prevent and Treatment of Osteoporosis, 2008







# Burden of osteoporosis

## **Osteoporosis – more than 200 million people**

- 30% postmenopausal women have osteoporosis
- Main osteoporosis complication is fracture
- Risk of lifelong possibility for radial, vertebral or hip fracture reaches 40%, nearly similar to CHD risk



#### Hip fracture rate increases



Reginster J-Y, Burlet N. Bone 2006;38:S4-S9 WHO Scientific Group WHO Technical Report Series 921;2003:1 Gulberg Bet al, Osteoporosis Int 1997;7:407-413. Johnell O, Kanis JA. Osteoporosis Int 2006;17:1726-1733 Europen Comission. Repot on osteoporosis in the European Community-action for prevention, 1998



The Science and Medicine of

# Comprehensive Management

New Dimensions, Novel Strategies, and Landmark Practice Advances in Fracture Reduction — *Screening, Monitoring, and Therapy:* **The Primary Care Perspective** 



Jointly Sponsored by the University of Massachusetts Medical School Office of Continuing Educ Funded by an unrestricted educational grant from Novartis Pharmaceuticals UNOVARTIS

#### **Osteoporotic fractures**

1,600,000 1,400,000 1,200,000 1,000,000 800,000 600,000 400,000 200,000 0 Breast cancer Heart disease OP Fx

### "Dowager's «hump»



Vittore Carpaccio, 1457

A. Rodin, 1885


# Fractures change patient's life tremendously

#### **Vertebral fracture**

- Back pain
- Height reduction
- Deformation and immobility
- Reduced lung function
- Increased fracture risk

#### **Hip fracture**

- Chronical pain
- Reduced mobility
- Increased further fracture risk
- Increased morbidity and lethality
- □ 10–20% of patients are in need of care



International Osteoporosis Foundation (IOF). Available at: http://www.iofbonehealth.org/facts-and-statistics.html. Accessed 23 May 2008. http://eristic-ragemail.blogspot.com/2008/05/deaths-of-immigrants-in-federal-custody.html

#### Hip fractures cause substantial clinical, social and economic burden




- Hip fractures significantly increase mortality, even in the age group under 65 year<sup>1</sup>
- 40% of women who fracture a hip will never be able to walk again without assistance, and less than 20% will recover to their pre-fracture competence in activities<sup>2</sup>
- Hip fractures are the most important factor contributing to the cost burden of osteoporosis, including hospitalisations<sup>3</sup>

<sup>1</sup>Center JR et al. Lancet 1999;353:878-882. <sup>2</sup>Cooper S. Am J Med 1997;103:12S-19S. <sup>3</sup>Burge et al. J Bone Miner Res2007;22:465-475

# Functional status of patients before and after hip fracture

Ability to	Before fracture (%)	6 months after fracture (%)
dress without assistance	86	49
reach something without assistance	90	32
walk without assistance	75	15
climb stairs	63	8
walk at least 900m	41	6
M Coopey 1002		







National Osteoporosis Foundation. Osteoporos Int 1998; 8(Suppl. 4):S1-S88

# A prior fracture is a precursor of subsequent fracture

- In women a fracture increases the risk of subsequent fracture by 86%<sup>1</sup>
- for 1 in 5 postmenopausal women with prior vertebral fracture, subsequent fracture is expected within a year<sup>2</sup>
- prior fragility fracture is reported in between 45% and 52% of women with hip fracture<sup>3-5</sup>
- women with prior fracture have an approximately 2-fold higher risk of suffering a hip fracture






C Mayo Foundation for Medical Education and Research. All rights reserved.

<sup>1</sup>Kanis JA et al. Bone 2004;285:375-382. <sup>2</sup>Linday R et al. JAMA 2001;285:320-323. <sup>3</sup>Lyles KW et al. ASBMR 2008. <sup>4</sup>Edward BJ et al. Clin Orthop Rel Res 2007;225-230. <sup>5</sup>McLelalan AR et al. (2004) Efectivness of Strattegies for the Secondary Prevention os Osteoporotic: Fractures in Scientific 9ceps 99030 NHS Qulity Improvement Scotland. <sup>6</sup>Klotzbuecher CM et al. J Bone Min Res 2000;15:721=739




## **Multiple roles of vitamin D**




# Vitamin D deficiency causes and influences various medical conditions

(Michail F Holick, 2008)






#### **Recomended concentrations of 25(OH)D3 in serum**



#### Correlation of age and vitamin D concentration in PC and control group males and vitamin D concentration in Latvia when synthesis of PTH is influenced




#### **Conclusions:**

Deficit of vit. D can be found in both PC and control group males. Nutrition does not provide the necessary intake of vitamin D. In order to assess the preventive effect of vit. D against PC it is suggested to use inactive forms of vitamin D, thus, increasing vit. D concentration in serum and enabling further prospective research.

*Meija L, Cauce V, Ignace G, Siksna I, Lietuvietis V, Lejnieks A*.D vitamīns uzturā un serumā priekšdziedzera vēža pacientiem un kontroles grupas vīriešiem. RSU ZR, 2011. Lejnieks A, Slaidina A, Zvaigzne A, et al. Medicina (Kaunas) 2013;49(7)

#### **Concentration of vit. D in summer and winter in Latvia**



#### Conclusions:

In order to avoid increased PTH stimulation, the optimum vit. D concentration in Latvia has to be at least 38 ng/mL.

**170,4%** of all healthy women had vit. D deficiency in winter and 59,8% in summer.

The highest rate of vit. D deficiency both, in winter and summer was found in postmenopausal women who don't take additional vit.D supplementation




#### Osteoporosis is curable

# Main principle of antiosteoporotic therapy – to avoid first and subsequent minimal trauma bone fractures


- Increase BMD
- Improve skeletal architectonics
  - Increase bone size and dimensions
  - Increase amount and thickness of trabeculae
  - Renew trabecular net binding
- Improve material features of the bone
  - Reduce bone turnover
  - Increase mineralisation
- Microdamage correction



#### **Drugs for treatment of osteoporosis**



### Women with osteoporosis often do not receive proper antiosteoporotic therapy for prolonged time






National Clinical Audit of Falls and Bone Healths (2007)

http://sitik.wordpress.com/2010/10/28/mengenal-tulang-berisiko-osteoporosis/

## **Bisphosphonate (BP) effects**


- \$\sum bone turnover
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
   \$
- A BMD in lumbar vertebrae and proximal hip
- □ ↓ vertebral fracture risk
- Various effects on hip fractures
- Quick effects on BMD and bone markers
- Quick effects on bone fracture risk
- Persuasive effect if used for prolonged periods
- Good research results in treatment of osteoporosis
- Safe to use for prolonged periods



**Edvard Munch** 


## **Possible side effects of BP**

- Necrosis of jaw
- Oesophageal ulcer, Ca
  - **Do not subscribe BP to patients with:** 
    - Barrett esophagus
    - Erosive gastritis
    - stomach ulcer
- Subtrochanteric fractures of femoral neck
- □ AF (seldom)





#### Strontium ranelate action principle

(currently restricted)



# Constant intake of high dose PTH promotes bone resorption, but intermittent low dose promote bone formation






#### **Before**

After


- Increases bone resorption
  - Large doses, prolonged intake
  - Promotes bone formation
    - Intermittent low doses
    - Increases differentiation and activity of osteoblasts
    - Decreases apoptosis of osteoblasts
- Increases thickness and amount of trabeculae
- Renew binding of trabeculae
- Increases diameter and strength of cortical bone

# Denosumab – human IgG antibody against RANKL, controls differentiation, activation and survival of osteoclasts



#### **Odanacatib (Cathepsin-K inhibitor) – new osteoporosis drug**

- Cathepsin-K enzyme responsible for collagen type 1 degradation
- CatK cysteine protease, with high influence on OsCl
- In mice reduced CatK synthesis causes increase of BMD and cortical bone surface
- During bone formation CatK concentration is 4-6 times higher
- CatK blocks bone formation
- Reduced synthesis of CatK increases BMD, but bone formation is not decreased





### Take home message

- Osteoporosis is an important society health problem
- Consider secondary causes of bone loss
- Lifestyle modification recommended
- Cortical bone porosity and thickness are important features
- Long-term osteoporosis treatment is safe and effective





http://www.thehotglove.com/2010/10/lady-florida-pulled-dui-offers-cop-grilled-cheese/

### Take a careful look at people! First impression is important, but not always complete!

